Indaptus Therapeutics (NASDAQ:INDP) Trading 6.3% Higher – Here’s Why

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s stock price shot up 6.3% on Tuesday . The company traded as high as $1.03 and last traded at $1.01. 9,030 shares were traded during trading, a decline of 57% from the average session volume of 21,207 shares. The stock had previously closed at $0.95.

Analyst Ratings Changes

Several brokerages recently commented on INDP. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Indaptus Therapeutics in a research note on Wednesday, October 16th. Maxim Group reduced their price target on shares of Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Indaptus Therapeutics Price Performance

The company has a market capitalization of $9.89 million, a PE ratio of -0.57 and a beta of 1.47. The stock has a 50-day simple moving average of $1.01 and a 200 day simple moving average of $1.45.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.15. As a group, research analysts predict that Indaptus Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.